Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Garetosmab→

Garetosmab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2097125-54-5
Molecular formula
C6472H10004N1712O2024S42
Molecular weight
145500 g/mol
Drug class
Activin A-neutralising human monoclonal antibodyactivin A/ALK2 pathway inhibitor
Mechanism of action
Binds activin A and prevents activation of the abnormal ACVR1/ALK2 signalling pathway implicated in fibrodysplasia ossificans progressiva (FOP), reducing formation of heterotopic bone and disease flare-ups.
Indications / reported uses
  • Reduction of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP) under the US FDA PASATRU indication (approved 19 August 2026)

Sources: US FDA — Pasatru approval announcement, 2026 · FDA Purple Book — PASATRU (garetosmab-grts), original approval 19 August 2026 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Garetosmab Environmental Risk Assessment (ERA) (the Garetosmab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.